- 163P Circulating tumour (ct) DNA next generation sequencing (NGS) in UK advanced non-small cell lung cancer (aNSCLC) patients (pts)Cui W.; Milner-Watts C.; Lyons H.; Yousaf N.; Minchom A.R.; Bhosle J.; Davidson M.; Scott S.; Faull I.; Nagy R.J.; O'Brien M.E.R.; Popat S.Journal of Thoracic Oncology, 2021, 16(4S).
- ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC)Yang, J-J.; Zhou, J.; Cheng, Y.; Li, M.; Zhao, Q.; Zhang, Z-Y.; Zang, A.; Fan, Y.; Zhou, Y.; Guo, J.; Zheng, Y.; Wu, Z.; Sun, J.; Xiang, X.; Wang, X.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)O. Martínez-Sáez; T. Pascual; F. Brasó-Maristany; N. Chic; B. González-Farré; E. Sanfeliu; A. Rodríguez; D. Martínez; P. Galván; A. Rodriguez Hernandez; F. Schettini; B. Conte; M.J. Vidal; B. Adamo; M. Muñoz; R. Moreno; E.M. Ciruelos; I. Faull; A. PratAnnals of Oncology, 2020, 31: s17.
会议论文
CtDNA dynamic detection reflects the clinical efficacy following treatment in NSCLC patients.
11阅读
